Intestinal mucosal barrier: a potential target for traditional Chinese medicine in the treatment of cardiovascular diseases
- PMID: 38469405
- PMCID: PMC10925767
- DOI: 10.3389/fphar.2024.1372766
Intestinal mucosal barrier: a potential target for traditional Chinese medicine in the treatment of cardiovascular diseases
Abstract
Cardiovascular disease (CVD) is a serious public health problem, and among non-communicable diseases, CVD is now the leading cause of mortality and morbidity worldwide. CVD involves multiple organs throughout the body, especially the intestinal tract is the first to be involved. The impairment of the intestinal mucosal barrier is considered a significant pathological alteration in CVD and also contributes to the accelerated progression of the disease, thereby offering novel insights for CVD prevention and treatment. The treatment of Chinese medicine is characterized by multi-metabolites, multi-pathways, and multi-targets. In recent years, the studies of Traditional Chinese Medicine (TCM) in treating CVD by repairing the intestinal mucosal barrier have gradually increased, showing great therapeutic potential. This review summarizes the studies related to the treatment of CVD by TCM (metabolites of Chinese botanical drugs, TCM formulas, and Chinese patent medicine) targeting the repair of the intestinal mucosal barrier, as well as the potential mechanisms. We have observed that TCM exerts regulatory effects on the structure and metabolites of gut microbiota, enhances intestinal tight junctions, improves intestinal dyskinesia, repairs intestinal tissue morphology, and preserves the integrity of the intestinal vascular barrier through its anti-inflammatory, antioxidant, and anti-apoptotic properties. These multifaceted attributes position TCM as a pivotal modulator of inhibiting myocardial fibrosis, and hypertrophy, and promoting vascular repairment. Moreover, there exists a close association between cardiovascular risk factors such as hyperlipidemia, obesity, and diabetes mellitus with CVD. We also explore the mechanisms through which Chinese botanical drugs impact the intestinal mucosal barrier and regulate glucose and lipid metabolism. Consequently, these findings present novel insights and methodologies for treating CVD.
Keywords: Chinese patent medicine; cardiovascular disease; gut microbiota; intestinal mucosal barrier; metabolites of Chinese botanical drugs; traditional Chinese medicine formulas.
Copyright © 2024 Liu, Wei, Wang, Zhang, Gao, Cheng and Chi.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
An overview of traditional Chinese medicine affecting gut microbiota in obesity.Front Endocrinol (Lausanne). 2023 Mar 1;14:1149751. doi: 10.3389/fendo.2023.1149751. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 36936157 Free PMC article. Review.
-
Traditional Chinese Medicine: A promising strategy to regulate the imbalance of bacterial flora, impaired intestinal barrier and immune function attributed to ulcerative colitis through intestinal microecology.J Ethnopharmacol. 2024 Jan 10;318(Pt A):116879. doi: 10.1016/j.jep.2023.116879. Epub 2023 Jul 5. J Ethnopharmacol. 2024. PMID: 37419224 Review.
-
Recent advances of traditional Chinese medicine against cardiovascular disease: overview and potential mechanisms.Front Endocrinol (Lausanne). 2024 Sep 30;15:1366285. doi: 10.3389/fendo.2024.1366285. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39403576 Free PMC article. Review.
-
Repairing gut barrier by traditional Chinese medicine: roles of gut microbiota.Front Cell Infect Microbiol. 2024 Jul 4;14:1389925. doi: 10.3389/fcimb.2024.1389925. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 39027133 Free PMC article. Review.
-
Intestinal Escherichia coli and related dysfunction as potential targets of Traditional Chinese Medicine for respiratory infectious diseases.J Ethnopharmacol. 2023 Sep 15;313:116381. doi: 10.1016/j.jep.2023.116381. Epub 2023 Mar 20. J Ethnopharmacol. 2023. PMID: 36940735 Review.
Cited by
-
Sex Differences in Cardiovascular Diseases: Exploring the Role of Microbiota and Immunity.Biomedicines. 2024 Jul 24;12(8):1645. doi: 10.3390/biomedicines12081645. Biomedicines. 2024. PMID: 39200110 Free PMC article. Review.
-
Isoliquiritigenin Promotes the Repair of High Uric Acid-Induced Vascular Injuries.Smart Med. 2025 Apr 4;4(2):e70000. doi: 10.1002/smmd.70000. eCollection 2025 Jun. Smart Med. 2025. PMID: 40303869 Free PMC article.
-
Unraveling the gut: the pivotal role of intestinal mechanisms in Kawasaki disease pathogenesis.Front Immunol. 2024 Nov 26;15:1496293. doi: 10.3389/fimmu.2024.1496293. eCollection 2024. Front Immunol. 2024. PMID: 39664384 Free PMC article. Review.
References
-
- Arakawa K., Ishigami T., Nakai-Sugiyama M., Chen L., Doi H., Kino T., et al. (2019). Lubiprostone as a potential therapeutic agent to improve intestinal permeability and prevent the development of atherosclerosis in apolipoprotein E-deficient mice. PLoS ONE 14 (6), e0218096. 10.1371/journal.pone.0218096 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources